AstraZeneca, Cancer Research UK, University of Newcastle deal

AstraZeneca's KuDos Pharmaceuticals Ltd. subsidiary exercised a 2004 option for exclusive, worldwide rights to a portfolio of DNA-dependent protein kinase (DNA-PK) inhibitors jointly owned by the un...